XERS Stock Recent News

Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aqueous formulations for certain drugs, improving stability and solubility. The company has seen significant revenue growth, with three commercially approved drugs generating $42 million in revenues in Q3 2023.

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it remains on track to be cashflow positive in the fourth quarter of 2024 as it updated its revenue and cash position guidance for its 2023 financial year. Ahead of investor meetings in San Francisco next week, the growth-oriented biopharmaceutical company said it expects to report total revenue at the top of its previous guidance range of $160 million to $165 million.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit “Events”.

Xeris Biopharma Holdings (NASDAQ:XERS) revealed its latest quarterly results that highlighted strong revenue growth driven by its commercial products. “We continue to demonstrate record revenue growth as we execute on our strategy,” CEO Paul Edick said in a statement.

Xeris Biopharma Holdings (NASDAQ:XERS) revealed significant strides in its financial performance and collaboration agreements. The pharmaceutical company announced an upward revision of its full-year 2023 financial guidance from $145-$165 million to $155-$165 million.

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that it and its Xeris Pharmaceuticals Inc. subsidiary have entered into separate, privately negotiated exchange agreements with certain holders of Xeris' outstanding 5% convertible senior notes which mature in 2025.

Xeris Biopharma Holdings Inc. is making strong progress on the top line and is on track to achieve a positive cash flow breakeven point in 2023. The company holds a substantial number of patents globally, contributing to its success in the pharmaceutical industry. Xeris Pharmaceuticals' notable product, Gvoke, has experienced significant market share expansion, providing reassurance for potential investors.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Thursday, September 28, 2023 at 3:00pm Eastern Time. A live webcast of the event will be avail.

Xeris Biopharma reports notable revenue growth in Q2 2023 for its main products, Gvoke, Keveyis, and Recorlev. The company's expenses have also increased, with a rise in the cost of goods sold and research and development expenses. Xeris has a satisfactory reserve for short-term needs but carries significant long-term debt, which may deter some investors.

Xeris Biopharma has reported another quarter of record revenue driven by continued strong demand for the biopharmaceutical company's products Gvoke, Keveyis, and Recorlev. For the quarter which ended on June 30, 2023, the company achieved sales of $38 million, up 50% year-over-year and 14% sequentially.